Статья
Основные подходы к диагностике и лечению острого коронарного синдрома во время пандемии новой коронавирусной инфекции COVID-19. Обзор литературы
Пандемия новой коронавирусной инфекции COVID-19 охватила более 180 стран мира. Одна из уязвимых когорт населения — пациенты с сердечно-сосудистыми заболеваниями. Отмечается особый патогенез воздействия вируса на организм и многообразие клинических проявлений COVID-19, а также сложности с ранней диагностикой. Другими неразрешенными проблемами являются вопросы маршрутизации, хирургического и терапевтического лечения больных с COVID-19 и другими соматическими патологиями. В отсутствии четко прописанных алгоритмов и рекомендаций лечение больных с острым коронарным синдромом (ОКС) в разных странах мира осуществляется по-разному. Много спорных вопросов вокруг лекарственного взаимодействия препаратов для лечения острых форм ишемической болезни сердца и препаратов для лечения COVID-19. Основываясь на имеющихся данных, отражены основные тенденции общего подхода в понимании организационных и лечебных мероприятий при оказании помощи больным с ОКС в период пандемии COVID-19.
1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; doi:10.1001/jama.2020.2648.
2. Yang J, Jing Yang, Zheng Ya, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020; doi:10.1016/j.ijid.2020.03.017.
3. Zheng YY, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; doi:10.1038/s41569-020-0360-5.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.
5. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; doi:10.1001/jamacardio.2020.1096.
6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. March 5, 2020; doi:10.1016/j.cell.2020.02.052..
7. Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept. 2012;2012:256294-256294. doi:10.1155/2012/256294.
8. Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARSCoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. March 3, 2020; doi:10.1007/s00134-020-05985-9.
9. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4; doi:10.1002/ddr.21656.
10. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Accessed March 19, 2020. https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAAC%20CAHA-statement-addresses-concerns-reusing-RA%20AS-antagonists-in-COVID-%2019.jsp
11. Shrestha SK. Statin drug therapy may increase COVID-19 infection. NMJ 2020;3(1). Epub ahead of print. doi:10.3126/nmj.v3i1.28256.
12. Thorp EB, Gallagher TM. Requirements for CEACAMs and Cholesterol during Murine Coronavirus Cell Entry. Journal Of Virology. 2004;78(6):2682-92. doi:10.1128/JVI.78.6.2682-2692.2004.
13. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002;110(5):597- 603. doi:10.1172/JCI16390.
14. Rawat SS, Viard M, Gallo SA, et al. Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Molecular Membrane Biology. 2003;20:243-54. doi:10.1080/0968768031000104944.
15. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9:125-38. doi:10.1038/nrm2336.
16. Walley T, Folino-Gallo P, Schwabe U, et al. Variations and increase in use of statins across Europe: data from administrative databases. BMJ. 2004;328:386-7. doi:10.1136/bmj.328.7436.385.
17. Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33(4):869-89. doi:10.1016/j.idc.2019.07.001.
18. Azhar EI, Hui DSC, Memish ZA, et al. The Middle East respiratory syndrome (MERS). Infect Dis Clin North Am. 2019;33(4):891-905. doi:10.1016/j.idc.2019.08.001.
19. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. Med Virol. 2020;92(4):424-32. doi:10.1002/jmv.25685.
20. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39(5):529-39. doi:10.1007/s00281-017-0629-x.
21. Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19 JAMA 2020. (online ahead of print). doi:10.1001/jama.2020.3633.
22. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3. doi:10.1007/s00134-020-05991.
23. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-8. doi:10.1016/j.cca.2020.03.022.
24. Zarychanski R, Houston DS. Assessing thrombocytopenia in the intensive care unit: the past, present, and future, Hematol. Am. Soc. Hematol. Educ. Program. 2017;(2017):660-6. doi:10.1182/asheducation-2017.1.660.
25. Tang N, Li D, Wang X, et al. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020. doi:10.1111/jth.14768.
26. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020.. doi:10.1111/jth.14817.
27. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. doi:10.1016/S0140-6736(20)30566-3.
28. Sarkisian L, Saaby L, Poulsen TS, et al. Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated Troponins. Am J Med. 2016;129:446e5-446e21. doi:10.1016/j.amjmed.2015.11.006.
29. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018;72:2231-64. doi:10.1093/eurheartj/ehy462.
30. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020.. doi:10.1016/j.pcad.2020.03.001.
31. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30120-1.
32. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3. doi:10.1038/s41586-020-2012-7.
33. Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. International Journal of Cardiology. 2020. doi:10.1016/j.ijcard.2020.03.087
34. Zhang L, Fan Y, Lu Z. Experiences and lesson strategies for cardiology from the COVID19 outbreak in Wuhan, China, by ‘on the scene’ cardiologists. European Heart Journal, 2020. doi:10.1093/eurheartj/ehaa266.
35. Tam CCF, Cheung KS, Lam S, et al. Impact of Coronavirus Disease 2019 (COVID19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China. Circulation: Cardiovascular Quality and Outcomes. 2020;13:e006631. doi:10.1161/CIRCOUTCOMES.120.006631.
36. Jing ZC, Zhu HD, Yan XW, et al. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. European Heart Journal. 2020. doi:10.1093/eurheartj/ehaa258.
37. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. doi:10.1001/jama.2020.1585.
38. Linschoten And M, Asselbergs FW. CAPACITY-COVID: a European registry to determine the role of cardiovascular disease in the COVID-19 pandemic. European Heart Journal. 2020. doi:10.1093/eurheartj/ehaa280.
39. Courand PY, Harbaoui B, Bonnet M, et al. Spontaneous Coronary Artery Dissection in a Patient with COVID-19 JACC: Cardiovascular Interventions. 2020. doi:10.1016/j.jcin.2020.04.006.
40. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. Journal of the American College of Cardiology. 2020. doi:10.1016/j.jacc.2020.03.031.
41. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477 doi:10.1016/j.lfs.2020.117477.
42. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6. doi:10.1136/thorax.2003.012658.
43. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126(3):703-14. doi:10.1053/j.gastro.2003.12.002.
44. Cvetkovic RS, Goa KL. Lopinavir/Ritonavir. Drugs. 2003;63(8):769-802. doi:10.2165/00003495-200363080-00004.
45. Itkonen MK, Tornio A, Lapatto-Reiniluoto O, et al. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther 2019;105:219-228. doi:10.1002/cpt.1099.
46. Marsousi N, Daali Y, Fontana P, et al. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. ClinPharmacokinet 2018;57:1347-1354. doi:10.1007/s40262-018-0637-6.
47. Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07/2011. Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc., May 2011.
48. Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. Circulation. 2017;136:1955-75. doi:10.1161/CIRCULATIONAHA.117.031164.
49. Shlyakhto EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russ J Cardiol. 2020;25(3):3801. (In Russ.) Шляхто Е.В., Конради А.О., Арутюнов Г.П., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. doi:10.15829/1560-4071-2020-3-3801.
50. Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79:838-46. doi:10.1111/bcp.12541.
51. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455-66. doi:10.1111/bcp.12075.
52. DeCarolis DD, Westanmo AD, Chen YC, et al. Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. Ann Pharmacother. 2016;50:909-17. doi:10.1177/1060028016660325.
53. Mulangu S, Dodd LE, Davey RT, Jr. et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019;381:2293-303. doi:10.1056/NEJMoa1910993.